Differential Utility Losses in Herpes Zoster Cases Between Vaccinated and Unvaccinated Subjects: A Meta-analysis of Three Clinical Trials
CONCLUSIONS: Recombinant zoster vaccine is effective in alleviating disease severity in breakthrough cases of herpes zoster. The results may be useful in distinguishing QALY losses between vaccinated and unvaccinated cohorts in health economics studies, particularly cost-effectiveness analyses.PMID:38662318 | DOI:10.1007/s40261-024-01355-1
Source: Herpes - Category: Infectious Diseases Authors: Nikolaos Giannelos Bernard Francq Desmond Curran Source Type: research
More News: Clinical Trials | Economics | Herpes | Infectious Diseases | Shingles (Herpes Zoster) Vaccine | Study | Vaccines | Varicella-Zoster Virus Vaccine